Yousef Hasan
Shreveport, LANPI 1194330761
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,554 of the $4,375 with a category attached, or 81.2%. It is spread thinly across 31 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations.
Across 133 payments — averaging $32.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$767
- GSK$694
- Novartis$507
- Daiichi Sankyo Inc.$378
- Incyte Corporation$280
- Johnson & Johnson$220
- plus $2K from 25 others
What the payments were for
- Food & beverage$3,55481%
- Education$52212%
- Other$2997%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 24 | $767 |
| GSK | 14 | $694 |
| Novartis | 14 | $507 |
| Daiichi Sankyo Inc. | 15 | $378 |
| Incyte Corporation | 4 | $280 |
| Johnson & Johnson | 7 | $220 |
| Regeneron Healthcare Solutions, Inc. | 3 | $168 |
| Beone Medicines USA, Inc. | 3 | $154 |
| E.r. Squibb & Sons, L.L.C. | 4 | $152 |
| Amgen | 1 | $129 |
| AbbVie | 2 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $112 |
| Bristol Myers Squibb | 4 | $69 |
| Eisai Inc. | 3 | $65 |
| Astellas Pharma US Inc | 4 | $62 |
| Pfizer | 3 | $54 |
| Merck | 3 | $54 |
| Tempus AI, Inc | 2 | $48 |
| Pharmacosmos Therapeutics Inc. | 2 | $44 |
| Sanofi | 2 | $39 |
| Geron Corporation | 2 | $38 |
| Genentech USA, Inc. | 2 | $34 |
| Bayer | 2 | $34 |
| Exelixis Inc. | 1 | $25 |
| Sobi, Inc | 1 | $25 |
| Gilead | 1 | $24 |
| Tersera Therapeutics LLC | 1 | $19 |
| Secura Bio, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Recordati_rare_diseases_inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $16,188 |
| JardianceEmpagliflozin | 11 | $14,728 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,483 |
| Morphine Sulfate ErMorphine Sulfate | 27 | $1,302 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $660 |
| Gabapentin | 24 | $612 |
| Oxycodone Hcl | 24 | $558 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 26 | $440 |
| Atorvastatin Calcium | 40 | $299 |
| Levetiracetam | 11 | $194 |
| Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide | 11 | $187 |
| Pantoprazole Sodium | 27 | $178 |
| Metformin Hcl | 20 | $111 |
| Lisinopril | 20 | $104 |
| Potassium Chloride | 11 | $101 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $54 | $16,18818 claims |
| AstraZenecaSymbicort | $767 | $2,48311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.